The first recombinant FVIII produced in human cells - an update on its clinical development programme

Haemophilia

Volumn 20, Issue S1, 2014, Pages 1-9

  Valentino, L A ^a   Negrier, C ^b   Kohla, G ^c   Tiede, A ^d   Liesner, R ^e   Hart, D ^f   Knaub, S ^g  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITÉ LYON 1   (France)

^c Octapharma RandD   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^f ROYAL LONDON HOSPITAL   (United Kingdom)

^g Octapharma AG   (Switzerland)

Author keywords

Efficacy; Haemophilia A; Human recombinant FVIII; Immunogenicity; Pharmacokinetics; Safety

Indexed keywords

EPITOPE; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ALLERGIC REACTION; ARTICLE; BLEEDING; CHILD HEALTH CARE; DRUG HALF LIFE; DRUG SAFETY; HAMSTER; HEMOPHILIA; HEMOPHILIA A; HUMAN CELL CULTURE; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPHYLAXIS;

EFFICACY; HAEMOPHILIA A; HUMAN RECOMBINANT FVIII; IMMUNOGENICITY; PHARMACOKINETICS; SAFETY;

BLOOD COAGULATION FACTOR INHIBITORS; CELL LINE; CLINICAL TRIALS AS TOPIC; FACTOR VIII; HEMOPHILIA A; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS;

EID: 84890321123     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12322     Document Type: Article

References (12)

1. Leyte A, van Schijndel HB, Niehrs C et al. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem 1991; 266: 740-6.
2. Kannicht C, Ramström M, Kohla G et al. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thromb Res 2013; 131: 78-88.
3. Sandberg H, Kannicht C, Stenlund P et al. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII. Thromb Res 2012; 130: 80817.
4. Hironaka T, Furukawa K, Esmon PC et al. Comparative study of the sugar chains of factor VIII purified from human plasma and from the culture media of recombinant baby hamster kidney cells. J Biol Chem 1992; 267: 8012-20.
5. Shen BW, Spiegel PC, Chang CH et al. The tertiary structure and domain organization of coagulation factor VIII. Blood 2008; 111: 1240-7.
6. Galili U. The alpha-Gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immunol Cell Biol 2005; 83: 674-86.
7. Macher BA, Galili U. The Galalpha1, 3Galbeta1, 4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim Biophys Acta 2008; 1780: 75-88.
8. Hilliard P, Funk S, Zourikian N et al. Hemophilia joint health score reliability study. Haemophilia 2006; 12: 518-25.
9. Kulkarni R, Karim FA, Glamocanin S et al. Results from a large multinational clinical trial (guardian™ 3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia 2013; 19: 698-705.
10. Lander ES, Linton LM, Birren B et al.; International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature, 2001; 409: 860-921.
11. Watson JD, Crick FHC. A structure for deoxyribose nucleic acid. Nature 1953; 171: 737-8.
12. Bucasas KL, Franco LM, Shaw CA et al. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J Infect Dis 2011; 203: 9219.